Clinical trials: Cancer (Solid Tumors)
Solid Tumours
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.
- Trial name
- NCT00743067
- Testing
- GSK1363089 (formerly XL880)
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Solid Tumor (Phase I), RAS Mutation
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
The goal of this clinical trial is to determine whether AN4035 is safe and tolerable in people with advanced or metastatic solid tumors that have Rat Sarcoma oncogene (RAS) mutated solid tumors and high levels of the CEACAM5…
- Conditions
- Solid Tumor (Phase I), RAS Mutation, CEACAM5
- Trial name
- NCT07686445
- Testing
- Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor.
- Where
- 2 sites in Australia
- Volunteers
- 228 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Neoplasms
Japanese Phase 1 Study of BMS-844203 (CT322)
The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies
- Trial name
- NCT01146171
- Testing
- BMS-844203 (CT-322)
- Where
- Japan
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.
This is an open-label, single-arm, dose escalation clinical study to evaluate the safety and preliminary efficacy of OVV-01 Injection in patients with advanced solid tumors, following both intravenous (iv.) and intratumoral (it.)…
- Trial name
- NCT07648472
- Testing
- OVV-01 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Joint Biosciences Ltd.
Gastrointestinal Tumors, Solid Tumors
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M24D1 for Injection in patients with locally advanced…
- Trial name
- NCT07279428
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumors
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821…
- Trial name
- NCT05216965
- Testing
- 9MW2821
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Metastatic Solid Tumor
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.
- Trial name
- NCT06235437
- Testing
- ASD141
- Where
- 2 sites in Taiwan
- Volunteers
- 21 people
- Sponsor
- Ascendo Biotechnology Co., Ltd.
Solid Tumor Refractory to Conventional Treatment
Phase I Study of FXS887 in the Treatment of Solid Tumors
This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors.
- Trial name
- FXS887-I101 (NCT07345637)
- Testing
- FXS887
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Solid Tumors
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or…
- Trial name
- NCT06307795
- Testing
- ANS014004
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 63 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Solid Tumors
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical…
- Trial name
- NCT01593228
- Testing
- Iniparib (SAR240550/BSI-201), Carboplatin, Doxorubicin HCL liposome injection
- Where
- 32 sites in United States, Belgium and 2 more
- Volunteers
- 37 people
- Sponsor
- Sanofi
Advanced Malignant Solid Tumours
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours.
- Trial name
- NCT06600022
- Testing
- SCTB41
- Where
- China
- Volunteers
- 441 people
- Sponsor
- Sinocelltech Ltd.
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Advanced Solid Tumors
A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
This study is a one-arm, open, multicenter phase 1b/2 clinical trial of PE0116combined with PE0105 in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D and observing the preliminary efficacy.The trial can…
- Trial name
- NCT06026501
- Testing
- PE0116,PE0105
- Volunteers
- 120 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Solid Tumors
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
- Trial name
- NCT00828919
- Testing
- axitinib, crizotinib
- Where
- 34 sites in United States, Czechia and 9 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Solid Tumor Malignancies
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This protocol will examine the safety of intravenous administration of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C.
- Trial name
- NCT01118819
- Testing
- Clostridium novyi-NT spores
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- BioMed Valley Discoveries, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.